Deepak V. Almeida

3.6k total citations
51 papers, 2.1k citations indexed

About

Deepak V. Almeida is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, Deepak V. Almeida has authored 51 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Infectious Diseases, 41 papers in Epidemiology and 13 papers in Molecular Biology. Recurrent topics in Deepak V. Almeida's work include Tuberculosis Research and Epidemiology (45 papers), Mycobacterium research and diagnosis (37 papers) and Cancer therapeutics and mechanisms (11 papers). Deepak V. Almeida is often cited by papers focused on Tuberculosis Research and Epidemiology (45 papers), Mycobacterium research and diagnosis (37 papers) and Cancer therapeutics and mechanisms (11 papers). Deepak V. Almeida collaborates with scholars based in United States, South Africa and Netherlands. Deepak V. Almeida's co-authors include J Grosset, Sandeep Tyagi, Eric L. Nuermberger, Paul J. Converse, Ian M. Rosenthal, Si-Yang Li, Nicole C. Ammerman, Rokeya Tasneen, William R. Bishai and Charles A. Peloquin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Genetics.

In The Last Decade

Deepak V. Almeida

51 papers receiving 2.1k citations

Peers

Countries citing papers authored by Deepak V. Almeida

Since Specialization

Citations

This map shows the geographic impact of Deepak V. Almeida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deepak V. Almeida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deepak V. Almeida more than expected).

Fields of papers citing papers by Deepak V. Almeida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deepak V. Almeida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deepak V. Almeida. The network helps show where Deepak V. Almeida may publish in the future.

Co-authorship network of co-authors of Deepak V. Almeida

This figure shows the co-authorship network connecting the top 25 collaborators of Deepak V. Almeida. A scholar is included among the top collaborators of Deepak V. Almeida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deepak V. Almeida. Deepak V. Almeida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Contribution of telacebec to novel drug regimens in a murine tuberculosis model 2024 ·Antimicrobial Agents and Chemotherapy ·(unknown), Sandeep Tyagi, Andrew Garcia, Deepak V. Almeida, Yong S. Chang, Si-Yang Li, (unknown), Paul J. Converse, Todd A. Black, Nader Fotouhi, Eric L. Nuermberger	1
2	Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis 2023 ·Antimicrobial Agents and Chemotherapy ·Deepak V. Almeida, (unknown), (unknown), Barry Hafkin, Khisimuzi Mdluli, Nader Fotouhi, Eric L. Nuermberger	7
3	Impact of Dose, Duration, and Immune Status on Efficacy of Ultrashort Telacebec Regimens in Mouse Models of Buruli Ulcer 2021 ·Antimicrobial Agents and Chemotherapy ·(unknown), Deepak V. Almeida, Paul J. Converse, Till F. Omansen, Eric L. Nuermberger	10
4	Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model 2020 ·Antimicrobial Agents and Chemotherapy ·Deepak V. Almeida, Paul J. Converse, Till F. Omansen, Sandeep Tyagi, Rokeya Tasneen, Jeongjun Kim, Eric L. Nuermberger	19
5	Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering 2020 ·PLoS Pathogens ·Brendon M. Lee, Liam K. Harold, Deepak V. Almeida, Livnat Afriat‐Jurnou, Htin Aung, Brian M. Forde, Kiel Hards, Sacha J. Pidot, F. Hafna Ahmed, A. Elaaf Mohamed, Matthew C. Taylor, Nicholas P. West, Timothy P. Stinear, Chris Greening, Scott A. Beatson, Eric L. Nuermberger, Gregory M. Cook, Colin J. Jackson	52
6	High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease 2018 ·Antimicrobial Agents and Chemotherapy ·Till F. Omansen, Deepak V. Almeida, Paul J. Converse, Si-Yang Li, Jin Lee, Ymkje Stienstra, Tjip S. van der Werf, J Grosset, Eric L. Nuermberger	13
7	Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer 2018 ·PLoS neglected tropical diseases ·Paul J. Converse, Deepak V. Almeida, Rokeya Tasneen, Vikram Saini, Sandeep Tyagi, Nicole C. Ammerman, Si-Yang Li, Nicole M. Anders, Michelle A. Rudek, J Grosset, Eric L. Nuermberger	20
8	Clofazimine has delayed antimicrobial activity againstMycobacterium tuberculosisbothin vitroandin vivo 2016 ·Journal of Antimicrobial Chemotherapy ·Nicole C. Ammerman, Rosemary V. Swanson, Asa Tapley, Chivonne Moodley, (unknown), John Adamson, Afton Dorasamy, Sashen Moodley, (unknown), Linda A. Bester, Sanil D. Singh, Deepak V. Almeida, J Grosset	44
9	Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis 2015 ·Proceedings of the National Academy of Sciences ·Sandeep Tyagi, Nicole C. Ammerman, Si-Yang Li, John Adamson, Paul J. Converse, Rosemary V. Swanson, Deepak V. Almeida, J Grosset	91
10	Accelerated Detection of Mycolactone Production and Response to Antibiotic Treatment in a Mouse Model of Mycobacterium ulcerans Disease 2014 ·PLoS neglected tropical diseases ·Paul J. Converse, Yalan Xing, Ki Hyun Kim, Sandeep Tyagi, Si-Yang Li, Deepak V. Almeida, Eric L. Nuermberger, J Grosset, Yoshito Kishi	28
11	Acceleration of Tuberculosis Treatment by Adjunctive Therapy with Verapamil as an Efflux Inhibitor 2013 ·American Journal of Respiratory and Critical Care Medicine ·(unknown), Sandeep Tyagi, Deepak V. Almeida, Mariama C. Maiga, Nicole C. Ammerman, William R. Bishai	132
12	Assessment of Clofazimine Activity in a Second-Line Regimen for Tuberculosis in Mice 2013 ·American Journal of Respiratory and Critical Care Medicine ·J Grosset, Sandeep Tyagi, Deepak V. Almeida, Paul J. Converse, Si-Yang Li, Nicole C. Ammerman, William R. Bishai, Donald A. Enarson, Arnaud Trébucq	92
13	Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy 2012 ·Journal of Antimicrobial Chemotherapy ·C. Andréjak, Deepak V. Almeida, Sandeep Tyagi, Paul J. Converse, Nicole C. Ammerman, J Grosset	17
14	Treatment of Tuberculosis with Rifamycin-containing Regimens in Immune-deficient Mice 2011 ·American Journal of Respiratory and Critical Care Medicine ·Ming Zhang, Si-Yang Li, Ian M. Rosenthal, Deepak V. Almeida, Zahoor Ahmad, Paul J. Converse, Charles A. Peloquin, Eric L. Nuermberger, J Grosset	46
15	BCG-Mediated Protection against Mycobacterium ulcerans Infection in the Mouse 2011 ·PLoS neglected tropical diseases ·Paul J. Converse, Deepak V. Almeida, Eric L. Nuermberger, J Grosset	40
16	Pharmacokinetics of Rifampicin and Clarithromycin in Patients Treated for Mycobacterium ulcerans Infection in Ghana 2008 ·46th Annual Meeting ·Jan‐Willem C. Alffenaar, Willemien A. Nienhuis, Femke de Velde, (unknown), A. Mireille A. Wessels, Deepak V. Almeida, J Grosset, Ohene Adjei, Donald R. A. Uges, Tjip S. van der Werf	1
17	Isoniazid or Moxifloxacin in Rifapentine-based Regimens for Experimental Tuberculosis? 2008 ·American Journal of Respiratory and Critical Care Medicine ·Ian M. Rosenthal, Ming Zhang, Deepak V. Almeida, J Grosset, Eric Nuermberger	49
18	In Vivo Validation of the Mutant Selection Window Hypothesis with Moxifloxacin in a Murine Model of Tuberculosis 2007 ·Antimicrobial Agents and Chemotherapy ·Deepak V. Almeida, Eric Nuermberger, Sandeep Tyagi, William R. Bishai, J Grosset	31
19	Dedicated decontamination: A necessity to prevent cross contamination in high throughput mycobacteriology laboratories 2007 ·Indian Journal of Medical Microbiology ·Camilla Rodrigues, Deepak V. Almeida, Shubhada Shenai, (unknown), Ajita Mehta	6
20	High Incidence of the Beijing Genotype among Multidrug-Resistant Isolates of Mycobacterium tuberculosis in a Tertiary Care Center in Mumbai, India 2005 ·Clinical Infectious Diseases ·Deepak V. Almeida, (unknown), Tester F. Ashavaid, Ajit Lalvani, Zarir Udwadia, Ajita Mehta	69

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact